Ibrutinib suppression of chronic lymphocytic leukemia endures in second year
The targeted therapy ibrutinib continues to stifle relapsed or resistant
chronic lymphocytic leukemia for patients in an extended clinical trial
while treatment side effects decline in frequency and severity over
time, researchers reported at the 55th American Society of Hematology
(ASH) Annual Meeting and Exposition.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Hematology | Leukemia